TrialThe Lancet. Oncology2019
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1,371 papers cite itlatest 60 shown
this paperpooled ittrialcites it